MedTrace Logo

Circulating Tumor Cells in High-Risk Prostate Cancer Treated With High-dose Radiotherapy and Hormone Therapy

NCT01800058 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2020-06-26

Study results available
· View outcomes & findings →

Summary

The detection and quantification of Circulating tumor cells CTCs in peripheral blood of patients with prostate adenocarcinoma may be useful at least for:

Getting a correct stratification of patients with high-risk prostate cancer (PCa).

Set the prognosis at baseline. Evaluate the response to different treatments (predictive value and monitoring).

Establish individualized therapies.

Conditions

  • Patients With High-risk Prostate Cancer

Sponsors & Collaborators

  • Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

    lead OTHER

Principal Investigators

  • Almudena Zapatero, MD, PhD, PI · Radiation Oncology Department_Hospital Universitario de La Princesa

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2018-12-21
Completion
2018-12-21

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01800058 on ClinicalTrials.gov